Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma

NCT03841565 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT03841565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03841565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Withdrawn
Start date
August 7, 2020
Completion date
February 9, 2022
Enrollment
0 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent plasma cell myeloma